Agilent Technologies Inc. (A) Trading Down 3.6%
Agilent Technologies Inc. (NYSE:A) fell 3.6% during mid-day trading on Thursday . The stock traded as low as $46.09 and last traded at $46.69, with a volume of 2,981,907 shares traded. The stock had previously closed at $48.43.
A number of research analysts have commented on the stock. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Deutsche Bank AG assumed coverage on shares of Agilent Technologies in a research report on Wednesday, June 1st. They issued a “hold” rating on the stock. Robert W. Baird lifted their price objective on shares of Agilent Technologies from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday. Evercore ISI lifted their price objective on shares of Agilent Technologies from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Morgan Stanley reiterated a “hold” rating and issued a $47.00 price objective (up from $44.00) on shares of Agilent Technologies in a research report on Tuesday, May 17th. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $47.61.
The company’s 50-day moving average price is $46.65 and its 200-day moving average price is $42.49. The stock has a market cap of $15.21 billion and a P/E ratio of 33.23.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 17th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.47 by $0.02. The company earned $1.04 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $0.44 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, equities research analysts forecast that Agilent Technologies Inc. will post $1.91 EPS for the current year.
In related news, Director James Cullen sold 16,697 shares of the firm’s stock in a transaction on Friday, May 27th. The stock was sold at an average price of $45.78, for a total value of $764,388.66. Following the transaction, the director now owns 92,613 shares in the company, valued at $4,239,823.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
A number of hedge funds have added to or reduced their stakes in A. Advisors Asset Management Inc. raised its stake in shares of Agilent Technologies by 0.5% in the fourth quarter. Advisors Asset Management Inc. now owns 32,792 shares of the company’s stock worth $1,371,000 after buying an additional 161 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Agilent Technologies by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 480,354 shares of the company’s stock worth $20,083,000 after buying an additional 5,981 shares during the last quarter. Suntrust Banks Inc. raised its stake in shares of Agilent Technologies by 28.8% in the fourth quarter. Suntrust Banks Inc. now owns 33,943 shares of the company’s stock worth $1,418,000 after buying an additional 7,597 shares during the last quarter. Schroder Investment Management Group purchased a new stake in shares of Agilent Technologies during the fourth quarter worth approximately $1,631,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Agilent Technologies by 43.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 164,500 shares of the company’s stock worth $6,878,000 after buying an additional 49,900 shares during the last quarter.
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.